ALS Limited (ASX:ALQ): FY26 Returns on Capital and Laboratory Growth

Aditi Sarkar

15 October 2026 03:29 PM AEDT

ALS Limited (ASX:ALQ): FY26 Returns on Capital and Laboratory Growth

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue reached A$3,320.1 million, an increase of 10.7%.
Underlying return on capital employed rose to 21.5% from 18.4%.
Commodities revenue grew 18.8%, supported by minerals testing activity.
Life Sciences revenue increased 6.0%, with mixed results among its businesses.
Free cash flow rose to A$674.1 million; net debt declined.

ALS Limited (ASX:ALQ) provides laboratory testing, inspection and analytical services across environmental, food, pharmaceutical, industrial and mineral markets. Its FY26 results, released in May 2026, showed growth in testing revenue and earnings alongside an increase in return on capital employed. The differing performances of its Commodities and Life Sciences operations are central to understanding the year’s results.

FY26 Revenue and Earnings Performance

ALS Limited (ASX:ALQ) reported FY26 revenue of A$3,320.1 million, compared with A$2,999.4 million in FY25, a 10.7% increase. Underlying earnings before interest and tax (EBIT) reached A$599.0 million from A$502.3 million, rising 19.3%. The underlying EBIT margin improved to 18.0%, compared with 16.7% in FY25. These figures are based on the company’s reported underlying measures, which exclude specified items.

Underlying net profit after tax (NPAT) for ALS Limited (ASX:ALQ) increased 25.8% to A$381.2 million from A$303.0 million. Statutory NPAT grew to A$318.7 million from A$256.2 million. The company attributed the underlying earnings increase partly to higher minerals exploration activity, favourable first-half currency effects and lower interest costs.

Why Return on Capital Employed Increased

Underlying return on capital employed for ALS Limited (ASX:ALQ) reached 21.5% in FY26, against 18.4% in FY25, an improvement of 309 basis points on the company’s reported figures. Return on capital employed measures operating profitability relative to the capital used in the business. The increase coincided with higher earnings and improved operating margins, particularly in Commodities.

Free cash flow generated was A$674.1 million in FY26, compared with A$590.6 million in FY25, while net debt declined to A$1,069.5 million from A$1,424.1 million. These measures provide additional context for ALS Limited (ASX:ALQ)’s financing capacity and capital allocation. The FY26 dividend per share was 42.5 cents, versus 38.6 cents in FY25.

Commodities and Life Sciences: Different Growth Rates

Commodities revenue for ALS Limited (ASX:ALQ) rose 18.8% to A$1,294.2 million. Its underlying EBIT increased 25.9% to A$381.5 million, with the margin rising to 29.5% from 27.8%. The company reported higher geochemistry sample volumes, better pricing in the second half and greater use of previously installed laboratory capacity. Minerals organic revenue grew 20.2%, while geochemistry organic revenue increased 22.7%.

Life Sciences revenue increased 6.0% to A$2,025.9 million, while underlying EBIT rose 10.2% to A$296.5 million. Its EBIT margin improved to 14.6% from 14.1%. Food testing recorded 7.2% organic revenue growth, while Environmental experienced weaker trading conditions in the Americas and integration challenges. The differing divisional results indicate that ALS Limited (ASX:ALQ)’s annual performance reflected more than one demand cycle.

Operating Considerations and FY27 Guidance

In its FY26 release, ALS Limited (ASX:ALQ) anticipated 13–15% organic revenue growth in Minerals for FY27 and targeted improved mid-single-digit organic revenue growth in Life Sciences. These are management expectations, not realised results. Relevant uncertainties include changes in mineral exploration expenditure, regional environmental testing demand, labour and equipment costs, currency movements and execution of operational improvements.

Key Insights

The FY26 figures show higher earnings, margins, cash generation and reported return on capital employed for ALS Limited (ASX:ALQ). Commodities contributed substantially to the improvement, whereas Life Sciences showed more varied trading conditions. Comparing divisional margins, cash flow and capital employed helps distinguish the sources of profitability from the scale of the laboratory network.

FAQs

Q: What does ALS Limited do?

A:It provides testing, inspection and analytical services to minerals, environmental, food, pharmaceutical and other industrial customers.

Q: How much revenue did ALS report in FY26?

A:FY26 revenue was A$3,320.1 million, up 10.7% from FY25.

Q: What was the FY26 return on capital employed?

A:Underlying ROCE was 21.5%, compared with 18.4% in FY25.

Q: Which segment grew faster in FY26?

A:Commodities revenue increased 18.8%, compared with 6.0% for Life Sciences.

Q: What risks affect its reported results?

A:Mineral exploration demand, regional testing conditions, operating costs, currency movements and operational execution can affect performance.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.